fluorodeoxyglucose f18 has been researched along with mrk 003 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buser, C; Clark, EA; Coppola, D; Draetta, GF; Efferson, CL; Giampaoli, S; Gibson, RE; Majumder, PK; Mesiti, G; Patel, S; Reilly, JF; Strack, PR; Sullivan, T; Tammam, J; Ware, C; Winkelmann, CT; Winter, C; Yeatman, T | 1 |
1 other study(ies) available for fluorodeoxyglucose f18 and mrk 003
| Article | Year |
|---|---|
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Topics: Amyloid Precursor Protein Secretases; Animals; Breast Neoplasms; Cyclic S-Oxides; Down-Regulation; Female; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Intracellular Signaling Peptides and Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Transgenic; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Receptor, ErbB-2; Receptors, Notch; Signal Transduction; Thiadiazoles; TOR Serine-Threonine Kinases | 2010 |